Promacta tended to boost platelet counts in patients with low-risk MDS, and helped those patients be independent of transfusions, too.
Nicholas Wrigley
Advertisement
Articles by Nicholas Wrigley
The addition of Cabometyx to Opdivo and Yervoy improved outcomes for patients with advanced kidney cancer, according to recent research.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
A Survivor's 30-Year Wait for Lymphedema Relief Ends with Hackensack's New Supermicrosurgery Robotic Procedure
2
Understanding Wills & Estate Planning: LiveLung Augusta’s October Meeting Empowers Patients and Families
3
Gastrointestinal Stromal Tumor: Comprehensive Patient Guide
4
FDA Grants Orphan Drug Designation to MNV-201 for Myelodysplastic Syndrome
5
